What is the recommended dose and frequency of oxybutynin (antimuscarinic medication) for adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

Adults: The usual dose is one 5-mg tablet two to three times a day. The maximum recommended dose is one 5-mg tablet four times a day. The recommended dose and frequency of oxybutynin for adults is:

  • Usual dose: 5 mg, two to three times a day
  • Maximum dose: 5 mg, four times a day 1

From the Research

The recommended dose of oxybutynin for adults is typically 5-10 mg taken orally once daily, with a maximum daily dose of 30 mg, as an extended-release formulation, due to its smoother plasma concentration-time profile and lower maximum plasma concentration compared to immediate-release formulations 2. When considering the treatment of overactive bladder, it's essential to weigh the benefits and risks of oxybutynin against other available options, such as beta-3 agonists, which may have a lower risk of dementia 3, 4.

  • The dose and frequency of oxybutynin may need to be adjusted based on individual response and tolerability.
  • Oxybutynin is also available as a transdermal patch (3.9 mg/day) applied twice weekly, and as a topical gel (10% gel, 1 gram) applied once daily.
  • Elderly patients may require lower doses due to increased sensitivity to anticholinergic effects.
  • Combination therapy with mirabegron, a beta-3 agonist, may be considered for patients with moderate-to-severe symptoms, as it has been shown to be effective and well-tolerated 5.
  • However, the risk of dementia associated with anticholinergic use, including oxybutynin, should be carefully considered, especially in patients with risk factors for dementia 3, 4.
  • Persistence and adherence with oxybutynin may be lower compared to mirabegron, which has been shown to have a longer time-to-discontinuation and higher adherence rates 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.